In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug.
The U.S. Food and Drug Administration decision makes GSK’s shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere.
Research shows that Americans, who have become less engaged with worship houses, community organizations and even their own family members in recent decades, have steadily reported an increase in feelings of loneliness.
The RESTORE Network is working with a specialized group of experts on clinical trials, testing new therapies and technologies to improve the quality of life for those with neurological disorders.
As pharmacists, we are in a perfect position in our role to connect with patients and to help them explore areas in their life that may have gone awry and that could use a new perspective and a new point of view.